VeganicSKN Limited – FDA Warning Letter, Jul 21, 2025

The FDA issued a warning letter to VeganicSKN Limited following an inspection of its manufacturing facility in Queensland, Australia, conducted from July 15 to 21, 2025. The inspection revealed significant violations of Current Good Manufacturing Practice (CGMP) regulations, rendering the company"s drug products adulterated under the Federal Food, Drug, and Cosmetic Act. Key issues included a failure to adequately investigate failing laboratory results; specifically, the company released a batch for the U.S. market while an investigation was still open and without identifying a root cause for the initial failure. Additionally, the firm failed to conduct identity testing on high-risk raw materials susceptible to toxic contamination, instead relying solely on unverified supplier reports. The FDA also identified a general lack of oversight by the company’s Quality Unit, which failed to ensure that manufacturing processes and laboratory controls met safety standards. To resolve these violations, VeganicSKN must perform a retrospective review of all failed tests, conduct independent safety testing on products currently on the market, and implement a comprehensive plan to remediate its quality systems. The company is also advised to hire an independent consultant to assist in achieving compliance. Due to these findings, the FDA has placed the company on an import alert, and a formal response is required within 15 working days.